UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000020134
Receipt No. R000023257
Scientific Title Prediction of the therapeutic response and adverse events to methotrexate by monitoring methotrexate-polyglutamates (MTX-PGs) concentration in erythrocytes in Japanese patients with rheumatoid arthritis (RA).
Date of disclosure of the study information 2015/12/09
Last modified on 2019/09/12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Prediction of the therapeutic response and adverse events to methotrexate by monitoring methotrexate-polyglutamates (MTX-PGs) concentration in erythrocytes in Japanese patients with rheumatoid arthritis (RA).
Acronym Study in Japanese patients with RA for prediction of the therapeutic response and adverse events to methotrexate by monitoring MTX-PG concentrations in erythrocytes.
Scientific Title Prediction of the therapeutic response and adverse events to methotrexate by monitoring methotrexate-polyglutamates (MTX-PGs) concentration in erythrocytes in Japanese patients with rheumatoid arthritis (RA).
Scientific Title:Acronym Study in Japanese patients with RA for prediction of the therapeutic response and adverse events to methotrexate by monitoring MTX-PG concentrations in erythrocytes.
Region
Japan

Condition
Condition Rheumatoid arthritis
Classification by specialty
Clinical immunology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To evaluate the pharmacokinetics and pharmacodynamics of MTX-PGs in erythrocytes in patients with RA and correlate them with their effects and adverse events.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes DAS28CRP improvement from baseline (delta DAS28CRP) > 1.2 at 24 weeks
Key secondary outcomes 1. MTX-PG levels at 12 and 24 weeks
2. DAS28CRP improvement from baseline (delta DAS28CRP) > 1.2 at 12 and 24 weeks
3. MTX-PG levels at 0, 1 and 6 hours
4. Radiological remission rate
5. Adverse event rate

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. Patients who met the 2010 American College of Rheumatology (ACR) /European League Against Rheumatism (EULAR) criteria for RA.
2. MTX-naive patients who are going to start oral MTX treatment and patients who have already been treated with a stable dose of MTX.
Key exclusion criteria 1. Patients who have already been treated with Leflunomide and biologics.
2. Patients who can not be treated with MTX.
3. Patients who are pregnant, breast-feed, and desire to be pregnant.
Target sample size 100

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Katsuya Nagatani
Organization Jichi Medical University
Division name Division of Rheumatology and Clinical Immunology, Department of Medicine
Zip code
Address 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, JAPAN
TEL 0285-58-7358
Email knagatani@jichi.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Katsuya Nagatani
Organization Jichi Medical University
Division name Division of Rheumatology and Clinical Immunology, Department of Medicine
Zip code
Address 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, JAPAN
TEL 0285-58-7358
Homepage URL
Email knagatani@jichi.ac.jp

Sponsor
Institute Jichi Medical University
Institute
Department

Funding Source
Organization Jichi Medical University
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 12 Month 09 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications https://www.ncbi.nlm.nih.gov/pubmed/27435295
Number of participants that the trial has enrolled 56
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2013 Year 07 Month 01 Day
Date of IRB
2013 Year 07 Month 01 Day
Anticipated trial start date
2013 Year 07 Month 01 Day
Last follow-up date
2019 Year 09 Month 12 Day
Date of closure to data entry
2019 Year 09 Month 12 Day
Date trial data considered complete
2019 Year 09 Month 12 Day
Date analysis concluded
2019 Year 09 Month 12 Day

Other
Other related information Patients with RA who give their written informed consent of this study and seen in the Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan and associated hospitals are enrolled in this study after July 2013. This study is performed using prospective longitudinal and cross-sectional study designs including adult MTX-naive patients who are going to start oral MTX treatment and patients who have already been treated with a stable dose of MTX at the time of inclusion in the study.
The patients provide about 2 mL of their blood which is needed to estimate MTX-PGs in erythrocytes.

Management information
Registered date
2015 Year 12 Month 09 Day
Last modified on
2019 Year 09 Month 12 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023257

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.